Stocks · Healthcare · Medical - Devices
Haemonetics Corporation HAE
$104.68 +0.30% Close, Oct 2, 2026 · NYSE · Market cap $4.76B
High qualityStrong trend
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned +114.5%, ahead of the S&P 500 by 99.4 percentage points.
- Earnings beat analyst estimates in each of the last 8 quarters (average surprise over the last four: +5.7%).
- Net debt is 3.6× EBITDA, a high level of leverage.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 30%
- EPS growth (TTM, YoY)Bottom 31%
- FCF growth (TTM, YoY)Top 27%
- Revenue growth, 3-year CAGRBottom 36%
- Revenue growth accelerationTop 25%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 17%
- Gross marginBottom 42%
- Operating marginTop 14%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Top 36%
- Net debt / EBITDA (lower is better)Bottom 22%
- Interest coverTop 18%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 25%
- Free-cash-flow yieldTop 14%
- EBITDA / enterprise valueTop 24%
- Sales / enterprise valueTop 49%
- P/E vs own 5-year history (lower is better)Bottom 17%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 15%
- 6-month returnTop 11%
- 1-year return vs S&P 500Top 12%
- Distance from 52-week highTop 6%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 45%
- Consecutive EPS beatsTop 8%
- Share of analysts rating BuyBottom 22%
- Upside to consensus price targetBottom 13%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 20%
- Maximum drawdown, 3 yearsTop 24%
- Beta vs S&P 500 (lower is better)Top 12%
- Net debt / EBITDA (lower is better)Bottom 22%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -2.0% | 0.4% | ↑ |
| EPS growth (YoY) | -39.0% | -37.6% | ↑ |
| Gross margin | 56.8% | 57.4% | ↑ |
| Operating margin | 16.1% | 18.2% | ↑ |
| FCF margin | 14.1% | 21.5% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 0.4% | -2.0% | ↑ | Bottom 30% |
| EPS growth (TTM, YoY) | -37.6% | -39.0% | ↑ | Bottom 31% |
| Gross margin | 57.4% | 56.8% | ↑ | Bottom 42% |
| Operating margin | 18.2% | 16.1% | ↑ | Top 14% |
| Net margin | 7.1% | 12.1% | ↓ | — |
| Free-cash-flow margin | 21.5% | 14.1% | ↑ | — |
| Return on invested capital | 8.6% | — | Top 17% | |
| Revenue growth, 3-year CAGR | 4.5% | — | Bottom 36% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -9.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +7.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 3.64×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 8.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 3.59%
- Shareholder yield
- 3.59%
- Share count change, 1 year
- -5.5%
- Share count change, 3-year CAGR
- -3.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 27, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 8
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +5.7%
- Average 2-day reaction, last 8
- +1.8%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $108.60
- Target vs current price
- +3.7%
- Analysts with a rating
- 21
- Share rating Buy or Strong Buy
- 57%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +5.6% | +1.7% | +9.3% | +23.1% | — |
| May 7, 2026 | +0.8% | +3.2% | +8.2% | +32.6% | +64.8% |
| Feb 5, 2026 | +3.1% | -1.4% | -12.8% | -2.6% | -10.1% |
| Nov 6, 2025 | +13.4% | +32.3% | +44.2% | +65.2% | +27.9% |
| Aug 7, 2025 | +8.9% | -26.6% | -28.9% | -28.6% | -34.0% |
| May 8, 2025 | +1.6% | +5.9% | +6.8% | +9.6% | +18.8% |
| Feb 6, 2025 | +0.8% | -11.6% | -13.9% | -5.7% | -10.4% |
| Nov 7, 2024 | +2.8% | +10.7% | +17.4% | +3.2% | -8.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $1.14 | $1.08 | +5.6% | $339.4M |
| May 7, 2026 | $1.29 | $1.28 | +0.8% | $346.4M |
| Feb 5, 2026 | $1.31 | $1.27 | +3.1% | $339.0M |
| Nov 6, 2025 | $1.27 | $1.12 | +13.4% | $327.3M |
| Aug 7, 2025 | $1.10 | $1.01 | +8.9% | $321.4M |
| May 8, 2025 | $1.24 | $1.22 | +1.6% | $330.6M |
| Feb 6, 2025 | $1.19 | $1.18 | +0.8% | $348.5M |
| Nov 7, 2024 | $1.12 | $1.09 | +2.8% | $345.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 51.3× | 35.9× | 81th | Top 25% |
| P/E (forward) | 19.7× | — | — | — |
| EV / EBITDA | 21.9× | — | — | Top 24% |
| EV / Sales | 4.22× | — | — | Top 49% |
| Free-cash-flow yield | 6.12% | — | — | Top 14% |
| Earnings yield | 1.95% | — | — | Top 25% |
P/E over the past five years
Range 17.0× – 126.1× since Jul 3, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +114.5%
- Earnings per share growth (TTM)
- -37.6%
- Change in P/E multiple
- +145.0%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 94
- Days above the 200-day average
- 92
- 50-day average slope (20 days)
- +13.4%
- 200-day average slope (20 days)
- +3.4%
- Distance from 50-day average
- +5.9%
- Distance from 200-day average
- +39.5%
- RSI (14)
- 54.3
- Relative volume
- 0.58×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 38.9%
- Volatility vs own 5-year history
- 63th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.40
- Correlation with S&P 500
- 0.12
- Current drawdown from 1-year high
- -3.8%
- Maximum drawdown, 3 years
- -51.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 8, 2021 | Jan 27, 2022 | -68.6% | 245 days | Not yet recovered |
| Jan 14, 2021 | Jan 27, 2021 | -11.6% | 8 days | 4 days (Feb 2, 2021) |
| Oct 27, 2020 | Nov 4, 2020 | -11.0% | 6 days | 3 days (Nov 9, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $4.76B
- P/E (TTM)
- 51.3
- EPS, diluted (TTM)
- $2.04
- Revenue (TTM)
- $1.35B
- 52-week range
- $47.75 – $110.45
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Revenue | $993.2M | $1.17B | $1.31B | $1.36B | $1.33B |
| Gross profit | $530.8M | $622.9M | $711.9M | $778.5M | $743.6M |
| Operating income | $80.8M | $156.0M | $164.9M | $221.8M | $241.4M |
| Net income | $43.4M | $115.4M | $117.6M | $167.7M | $97.3M |
| EPS (diluted) | $0.84 | $2.24 | $2.29 | $3.31 | $2.05 |
| Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $345.5M | $348.5M | $330.6M | $321.4M | $327.3M | $339.0M | $346.4M | $339.4M |
| Net income | $33.8M | $37.5M | $58.0M | $34.0M | $38.7M | $44.7M | -$20.1M | $33.0M |
| EPS (diluted) | $0.66 | $0.74 | $1.17 | $0.70 | $0.81 | $0.95 | -$0.44 | $0.72 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Operating cash flow | $172.3M | $273.1M | $181.8M | $181.7M | $293.2M |
| Capital expenditure | -$96.5M | -$110.2M | -$38.1M | -$39.3M | -$32.8M |
| Free cash flow | $75.8M | $162.9M | $143.6M | $142.4M | $260.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $6.5M | -$75.0M | $1.3M | -$226.9M | -$167.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $223.4M
- Total assets
- $2.37B
- Total liabilities
- $1.53B
- Total debt
- $1.17B
- Net debt
- $950.8M
- Shareholders’ equity
- $837.1M
As of Jun 27, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 3,424,696
- Days to cover
- 5.69
- Change vs previous report
- +19.6%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Dec 3, 2012
- 2-for-1
- Jan 11, 1993
- 2-for-1